ABR215050 Tasquinimod DNA Synthesis Inhibitors Cas 254964-60-8
ABR215050 Tasquinimod DNA Synthesis Inhibitors Cas 254964-60-8
+ AII PRODUCTS
- Prostaglandins - Custom Synthesis - PARP Inhibitors - PI3K Inhibitors - FAK Inhibitors - AKT Inhibitors - C-Kit Inhibitors - VEGFR Inhibitors - c-Met Inhibitors - CDK Inhibitors - CYP17 Inhibitors - DNA/RNA Inhibitors - mTOR Inhibitors - SRC Inhibitors - Others
Product
|
Size |
Price |
Stock |
Quantity |
|---|---|---|---|
|
Get Quotation Now Add to Cart Bulk Inquiry |
|||
AddThis Sharing Buttons
Share to FacebookFacebookShare to TwitterTwitterShare to PrintPrintShare to EmailEmailShare to PinterestPinterestShare to GmailGmailShare to LinkedInLinkedInShare to Email AppEmail AppShare to TumblrTumblrShare to MoreAddThis
Shipping and handling fee USD40, Free delivery is qualified when the total value of your order exceeds USD500.If the item is temporarily out of stock. Please email to order@pharm-intermediates.com,we will inform you when we have it in stock.
Chemical Information
|
Product name:ABR215050 Tasquinimod |
Purity:98% min |
|
CAS NO:254964-60-8 |
Solubility:DMSO42 mg/mL (103.36 mM) |
|
Molecular Formula:C20H17F3N2O4 |
Package:Package according to customer requirements |
|
Molecular Weight:406.355 |
Storage:Store at -20℃ |
Quality control
Remarks
Tasquinimod, also known as ABR215050, is a quinoline-3-carboxamide linomide analogue with antiangiogenic and potential antineoplastic activities. Tasquinimod has been shown to decrease blood vessel density but the exact mechanism of action is not known. This agent has also been shown to augment the antineoplastic effects of docetaxel and androgen ablation in a murine model of prostate cancer involving human prostate cancer xenografts.
Related Prodcuts:
Etoposide; Etoposide phosphate; ML-323; BMH-21; Nexturastat A; TMP269; GSK2606414; ELR510444; Chidamide; Inauhzin; CW069; Purvalanol A; Purvalanol B; JW55; Tenovin-6; Tenovin-6 HCL; RKI-1447; AZD2461
References
[1].Isaacs JT, et al. Tasquinimod Is an Allosteric Modulator of HDAC4 survival signaling within the compromised cancer microenvironment. Cancer Res. 2013 Feb 15;73(4):1386-99.
[2].Isaacs JT, et al. Anti-cancer potency of tasquinimod is enhanced via albumin-binding facilitating increased uptake in the tumor microenvironmen
Get in Touch
Have questions about our products or want to discuss a custom order? Our team is ready to help you.